Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide has a half-life of roughly one week, which means its concentration in your bloodstream gradually falls between injections. Most people on Wegovy notice this as a subtle shift: appetite returns a little more forcefully in the days before their next dose, and some describe a dip in how controlled eating feels. This is not a sign the medicine has stopped working. It reflects normal pharmacokinetics — and it is worth understanding properly, because the experience often shapes how people feel about their treatment overall. These are prescription-only medicines; a GPhC-registered prescriber assesses whether semaglutide is clinically appropriate for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You are not imagining it, and you are not alone in noticing it. A question our prescribers hear regularly is some version of: "everything feels fine by Wednesday, then by Saturday I'm fighting cravings again, is that normal?" The short answer is yes, and the reason sits in the drug's pharmacology rather than in anything you are doing wrong.
Semaglutide works by activating GLP-1 receptors in the brain and gut, slowing how quickly the stomach empties and signalling satiety to the hypothalamus. After each weekly injection, plasma levels rise over two to three days, reach a peak, and then begin a steady decline over the remaining days of the week. By the time you are approaching the next injection, concentrations are at their lowest point in the cycle. The appetite-suppressing and gastric-emptying effects follow that curve, so the last one or two days before your next dose can feel noticeably different from the middle of the week. You can read more about how this pattern specifically plays out on our page covering whether Wegovy wears off at the end of the week.
The NHS patient-level information for semaglutide on NHS.uk explains the general pharmacology and what to expect between doses, and is a useful reference alongside your Patient Information Leaflet.
For most people, the end-of-week dip becomes less disruptive over time. There are a few reasons for this. First, steady-state blood levels (where the peaks and troughs even out somewhat across the weekly cycle) take around four to five weeks to establish after any given dose. Early in treatment, or just after a dose increase, the fluctuation can feel sharper than it will once your system has settled. Second, as the titration schedule progresses and your maintenance dose increases, the overall therapeutic effect deepens, and the trough represents a smaller relative drop from a higher baseline.
Certain things can make the trough more noticeable. Dehydration and insufficient protein intake both amplify hunger signals; eating patterns that rely heavily on high-glycaemic foods can cause blood sugar swings that overlap with the pharmacological dip and feel more severe as a result. Disrupted sleep sharpens appetite hormones independently of semaglutide, so a poor night before the injection day can make the end-of-week experience feel worse than it is. These are practical, modifiable factors, not reasons to conclude the medicine is failing.
If you are weighing up how this pattern compares between semaglutide and Wegovy specifically, our page on whether Wegovy's effects wear off covers that angle in detail.
There is a difference between noticing that hunger returns a little before the next injection (expected, pharmacologically normal) and finding that the last two days of the week consistently undo your progress, cause significant distress, or leave you feeling that the treatment is not holding. The latter warrants a clinical conversation rather than quiet resignation.
A few scenarios deserve attention. If the injection day itself is not consistent (taking the dose a day early one week and a day late the next creates artificial variation in trough depth), regularising the timing often helps. Injection technique and site rotation can affect absorption; poor technique is a surprisingly common contributor to inconsistent effect. And in some cases, the dip at a current dose is simply a signal that titration to the next dose level is clinically appropriate, something a prescriber can assess properly.
For background on the broader pattern of how and when semaglutide's effects shift across the weekly cycle, our page on when semaglutide wears off maps out the timeline in more detail. Separately, our semaglutide overview covers the full picture of how this medicine works in a UK context. If you are also curious about how Wegovy is priced privately and what is included in a legitimate prescription service, our Wegovy price comparison page sets out what those costs cover.
It is also worth noting that semaglutide is a prescription-only medicine, and the STEP 1 phase 3 trial (published in the New England Journal of Medicine and one of the foundations for Wegovy's UK licence) studied these effects in controlled conditions with consistent weekly dosing and clinical oversight throughout. Real-world experience can diverge from trial conditions precisely because the practical details (injection timing, technique, dose, lifestyle factors) vary. That is exactly what ongoing clinical review is for.
A few things tend to help with the end-of-week experience. Keeping injection day fixed (the same day each week) removes one variable entirely. Staying well-hydrated and maintaining adequate protein intake through the trough days supports satiety independently of the drug. Some people find that planning lighter, more structured meals on the days before their injection, rather than trying to eat intuitively, removes the decision fatigue that makes the dip harder to manage.
Reach for medical help promptly (not just your next scheduled review) if you experience severe nausea or vomiting that is preventing you from keeping fluids down, severe stomach pain (particularly pain that radiates to the back), signs of an allergic reaction, or any symptoms that feel acute rather than gradual. These warrant urgent assessment. For non-urgent questions about how your treatment is going, the aftercare team at a regulated service should be your first call. Our FAQs page covers many common treatment questions, or you can reach our team directly.
If you are not yet on treatment and are thinking about whether semaglutide is right for you, our Wegovy page covers the full licensed indication and eligibility picture. The clinical team at nume reviews every consultation personally, a named prescriber, not software, reads your answers and makes the clinical decision. You can start your free consultation if you want to explore whether this is a suitable route for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.